Yes, companies can appeal the findings of a drug quality audit in Japan. They must submit a formal request to the Pharmaceuticals and Medical Devices Agency (PMDA) or relevant authority, providing evidence or arguments to support their case. The appeal process involves a review and potential re-evaluation of the audit findings.
